Evotec Investor Presentation Deck
evotec
Key challenges
R&D model is
inefficient
"One drug fits all"
is outdated
New modalities did not
solve all problems
Emerging technologies
are still very fragmented
PAGE 8
Bringing Probability of Success up is key leverage for better IRR¹)
Current challenges in R&D
Challenging returns due to
"too late and "expensive failure"
90% of drugs are efficacious
only in 50% of patients
9% of Phase I biologics
receive approval²)
Precision medicine toolkit,
OMICS platforms, and AI/ML
Development costs per asset increase
Cost per asset doubled since 2010, in US$ m
~2,500
1,188
2010
2020
Commercial returns decrease
IRR since 20104)
~10
2010
~23)
2020
*****
*****
¹) IRR = Internal Rate of Return
2) https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2021/files/reports/2021-clinical-development-success-rates-2011-2020-v17.pdf
3 excl. Covid-19 vaccines
4) Sources: Deloitte - Centre for Health Solutions: Ten years on measuring the return of pharmaceutical innovation 2020; Evaluate Pharma - World Preview 2018 / World Preview 2020
Pos UP
+100%
-80%
*da
...
9.g.
30
...
30²..
10
0.0
@***
682
*
34. .08.
....
::**
B...View entire presentation